Abstract: Suspensions of PBBMA, characterized in that they comprise PBBMA in the form of finely ground particles and contain suspending agents chosen from among xanthene gums, anionic or nonionic purified, sodium modified montmorilonite, naphthalene sulfonic acid-formaldehyde condensate sodium salt, sodium or calcium or ammonium salts of sulfonated lignin, acrylic acids/acrylic acids ester copolymer neutralized—sodium polycarboxyl, and wetting agents chosen from among alkyl ether, alkylaryl ether, fatty acid diester and sorbitan monoester types, polyoxyethylene (POE) compounds.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: A stable bleached shellac and an improved method for making stable bleached shellac is provided which involves precipitating bleached stable shellac from a pre-shellac solution at a pH of from 5.0 to 6.8, preferably from 5.0 to 6.5, most preferably from 5.0 to 6.0. The stable particulate shellac and the stable shellac solution, have a longer shelf life than conventional shellac. The stable shellac solution is comprised of solubilized particulate shellac in a solvent, most preferably ethanol. The stable particulate shellac and the stable shellac solution have a pH of from 4 up to less than 5 or from 5.0 to 6.8, more preferably from 5.0 to 6.5, even more preferably from 5.0 to 6.3, most preferably from 5.0 to 6.0.

Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

Abstract: The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.

Abstract: A transfer-resistant make-up or care composition, comprising: a fatty phase, and a volatile solvent comprising a linear decamethyltetrasiloxane and at least one additional solvent which has an evaporation speed that is greater than the evaporation speed of the linear decamethyltetrasiloxane.

Abstract: The present invention provides a new simple polymeric matrix tablet that delivers highly soluble drugs over long periods of time and is easy to manufacture. More specifically, the drug is first granulated with or encapsulated in a swellable polymer, such as a gum, to form a granule. This granule is disposed in a matrix of a more swellable, erodible polymer, such as HPMC or Polyethyleneoxide, and optionally includes pectin. The more swellable erodible polymer has a diffusion rate coefficient which is greater than the diffusion rate coefficient of the relatively less swellable polymer. It is this difference in diffusion rate coefficients between the first and second polymers which controls the rate of drug release and allows the system to approach zero order drug delivery over the drug release period. Other advantages which the present invention holds over existing systems including ease of manufacturing and reproducibility of release profiles under well defined hydrodynamic conditions.

Abstract: The present invention relates to sustained-release formulations using alginate gel beads and methods thereof.

Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: Sustained release compositions comprising a drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

Abstract: Process is provided for preparing an oral solid rapidly disintegrating freeze-dried dosage form of a pharmaceutically active substance having an unacceptable taste, wherein prior to freeze drying, a suspension of uncoated or coated coarse particles of a pharmaceutically active substance in a carrier material is cooled to reduce the viscosity and minimize release of the active substance during processing, as well as beyond the point of disintegration of the form in the mouth, to minimize bad taste from the drug.

Abstract: This invention relates generally to two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired. In particular, they are useful as tissue sealants, in promoting hemostasis, for drug delivery, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

Abstract: The invention is directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier, the hydrogel component of the carrier ranging from about 0.3 to 3.0% of the composition and having a molecular weight of about at least 10,000 Daltons. The composition contains about 25% to about 40% bone powder and can be additionally provided with BMP's and a sodium phosphate buffer.

Abstract: Alkylene oxide polymer compositions having particular molecular weight distributions are disclosed. As a result of the molecular weight distributions, the disclosed alkylene oxide polymer compositions are suitable, among other things, for the manufacture of films, e.g., for use in manufacturing soft gel capsules. Capsules made from the disclosed alkylene oxide polymer compositions can provide enhanced resistance to crosslinking often caused by liquid filling materials, e.g., polyethylene glycol, used in gelatin capsule manufacture.

Abstract: A process is claimed whereby an aqueous solution of agar, in which most (ideally all) 4-linked residues consist of 3,6-anhydro-L-galactose, is subjected to partial acid hydolysis and upon neutralization following the time appropriate for the chosen conditions, a low strength gel is obtained, from which, contrary to expectations, a polyagarobiose can be obtained by freeze-thawing and straining, thereby eliminating undesirable agaroid materials without the appropriate 3,6-anhydrogalactosyl content. The appropriate time of hydrolysis depends on initial gel strength, pH, counterion concentration and temperature. As an example, agar (gel strength 700 g/cm2, made to 1.86% solution) pH 3.25, counterion citrate (360 mg/L) at 96° C. requires 25 minutes to yield a material with an eventual gel stregth (1.5% solution) of 40 g/cm2. A stabilized product can be prepared by reducing terminal anhydrogalactosyl residues with sodium borohydride.

Abstract: Crushable gel beads 10 formed of an agar complex provide novel cosmetic, pharmaceutical, etc. delivery vehicles for topical delivery of biologically or cosmetically active agents. Preferred agar beads 10 are complexes of a continuous phase of agar gel 12 in a self-supporting solid or semi-solid form with a restraining polymer 14. Entrapped in and dispersed randomly throughout each agar bead 10 is a water-soluble, preferably polar, restraining polymer 14, preferably a quaternized cationic polymer, such as polyquaternium 24 or steardimonium hydroxyethylcellulose. Various active agents 16 may be bound to restraining polymer 14, for example ascorbic acid, lactic acid or papain. Methods of manufacture are also described.

Abstract: In one embodiment, this invention relates to a pharmaceutical composition for oral administration consisting essentially of a gelatin at a concentration up to 5% by weight as a carrier, a solvent, and, as an active ingredient, a dopamine agonist. Alternatively, the invention relates to a composition that takes the form of a solid, unitary fast-dispersing dosage form comprised of a network of an active ingredient after and a water-soluble or water dispersible matrix forming agent or carrier which is inert towards the active ingredient after subliming solvent from the composition in the solid state. The dosage is designed to completely disintegrate within 1 to 30 seconds of being placed in the oral cavity. Compositions which further comprise an anti-emetic and/or an opioid antagonist are also provided herein.

Abstract: This invention relates generally to two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired. In particular, they are useful as tissue sealants, in promoting hemostasis, for drug delivery, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

Abstract: A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35° C. to about 65° C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40° C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.

Abstract: The invention relates to a composition, in pellet form, useful for the nutritional and/or medicinal supplementation of ruminants and a method for admixing the pellets with foodstuff. The pellet contains granules of one or more active ingredients/principles protected against degradation in toe rumen and one or more binding agents capable of being solubilized, crosslinked or melted. Optionally, the pellet may also contain an unprotected active ingredient for release in the rumen. The pellet may further contain a disintegrating agent and/or filler.

Abstract: A process for the production of an extremely flexible patch having a dermal or transdermal action and having an adhesive matrix layer which comprises the active compound and is provided with a detachable protective layer on a side facing the skin is characterized in that the matrix layer is not covered on the side facing away from the skin but is given a non-adhesive treatment on its open surface.

Abstract: Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: A solid composition for topical application comprising, in an aqueous phase, a gelling system comprising (i) gellan gum, (ii) at least one other hydrocolloid chosen from the group formed by xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, agar-agar, carrageenans, alginates, carob gum, guar gum, gum arabic, karaya gum, gum tragacanth, ghatti gum, pectins, gelatin, caseinates and hydroxypropylguar, and (iii) at least one amphiphilic polymer comprising at least one fatty chain and at least one hydrophilic unit.

Abstract: The present invention relates to mucoadhesive compositions comprising a safe and effective amount of a gastrointestinal active; from about 1.5% to about 10%, by weight of the composition, of a clay component; and from about 0.01% to about 1%, by weight of the composition, of a gum component. Alternatively, the clay component can be a titanium dioxide or a silicone dioxide component. The mucoadhesive compositions also preferably comprise up to about 2% by weight of the composition, of a non-ionic component such as methyl cellulose. The present invention also relates to methods of prevention and treatment of gastrointestinal tract disorders in humans or lower animals by orally administering a composition of the present invention.

Abstract: A solid composition for topical application comprising, in an aqueous phase, a gelling system comprising (i) gellan gum, (ii) at least one other hydrocolloid chosen from the group formed by xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, agar-agar, carrageenans, alginates, carob gum, guar gum, gum arabic, karaya gum, gum tragacanth, ghatti gum, pectins, gelatin, caseinates and hydroxypropylguar, and (iii) at least one amphiphilic polymer comprising at least one fatty chain and at least one hydrophilic unit.

Abstract: A pharmaceutical composition is provided containing an admixture of phenytoin sodium and an erodible matrix which extends the release of the phenytoin sodium over about a two hour period. The erodible matrix comprises binder(s) and diluent(s) which control the release of drug from the pharmaceutical composition. The erodible matrix can further comprise an alkaline pH modifier.

Abstract: Compositions, devices, and methods for transdermal administration of a drug are disclosed using a novel permeation enhancer mixture comprising a monoglyceride and ethyl palmitate. The monoglyceride/ethyl palmitate permeation enhancer is a potent permeation enhancer and provides stable systems which are more readily characterized. Additionally, ethyl palmitate cosolvent systems are more readily processed at manufacturing conditions thus providing further advantages over other cosolvents.

Abstract: A powder composition containing at least one fat-soluble vitamin dispersed in a matrix of a natural polysaccharide gum or a mixture of gums having an emulsifying capacity and/or a protein or a mixture of proteins having an emulsifying capacity. The fat-soluble vitamin in the powder compositions is in the form of droplets having an average diameter in the range of about 70 to about 200 nm. Tablets, beverages and beverage concentrates, foods, cosmetics and pharmaceuticals containing the powder composition can be made.

Abstract: A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.

Abstract: The present invention provides compositions and methods for increasing absorption of poorly absorbable antibiotics, particularly third generation cephalosporin antibiotics, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a poorly absorbable antibiotic, and a cationic binding agent contained within the biopolymer such that the binding agent is tonically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antibiotic.

Abstract: This invention relates to a composition containing a hydrophobic solvent, a network polymer and a flow control agent which is useful in healing wounds. The composition of this invention may be applied directly to a wound to create a structured occlusive dressing. The dressings of this invention do not migrate, but maintain their integrity at skin temperature, and encourage the creation of a moist wound environment while protecting the wound in order to accelerate healing.

Abstract: The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

Abstract: A method for preparing solid rapidly disintegrating dosage forms shaped as biconvex tablets having symmetrical top and bottom surfaces and dosage forms obtainable thereby.

Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca—P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.

Abstract: The present invention relates to a delayed-release pharmaceutical composition which is in the form of tablets prepared by direct tableting and consisting of at least one active principle and a matrix which gives the said composition its delayed-release effect, characterized in that the said matrix consists at least in part of pregranulated polysaccharides of high molecular weight and of synthetic or natural origin.

Abstract: A topical composition for impregnating a bandage comprises zinc oxide in a stable oil in water emulsion. The emulsion comprises one or more fats or oils, one or more emulsifying agents, at least one water soluble gum and water. No preservative is required.

Abstract: The present invention is an dietary supplement which inhibits the assimilation of dietary fat during digestion, and method of making and using the same. The composition includes surfactant and non-digestible dietary fiber. In a preferred embodiment of the invention, the composition further comprises an emulsifying agent. The composition may be taken before, during or after eating.

Abstract: Disclosed is a method for the therapeutic treatment of pain related to wind up in a human or animal. The method of the invention is practiced by administering to the subject an effective amount of an analgesic pharmaceutical composition which includes a NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form. The immediate release form and sustained release forn are present in sufficient amounts to diminsh or abolish wind up.

Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

Abstract: A crosslinkable macromer system that includes two or more polymer-pendent polymerizable groups and one or more polymer-pendent initiator groups. The polymerizable groups and the initiator group(s) can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility.

Abstract: A flexible intra-oral bandage and kit thereof including an hydrolyzable powder/water-wettable fiber mixture enclosed in a flexible, water-permeable, non-stick envelope. The envelope is immersed in water or medication so that the liquid is absorbed through the envelope to wet the hydrolyzable powder/water-wettable fiber mixture and form a moldable tacky gel. The envelope is then removed from the gel and the gel is manually molded and placed in a desired location in a patient's oral cavity. The kit can also be used as a drug delivery system to deliver medication to a patient through the oral cavity.

Abstract: The invention is directed to methods and pharmaceutical compositions for the topical administration of opioid analgesic drugs such as morphine. In particular, the invention relates to topical administration of an opioid analgesic agent, e.g., morphine sulfate, in admixture with a skin- or mucosal-specific penetration enhancer, to produce a localized analgesic effect in inflamed or non-inflamed skin or mucosal tissue, and without a transdermal or transmucosal migration of opioid agent, e.g., into the systemic circulation.

Abstract: A gelatin with increased oxygen content for pharmaceutical, cosmetic and/or veterinary use. The gelatin comprises a gelling agent and a solvent, furthermore oxygen in a substantially even distribution with a pressure exceeding normal atmospheric pressure, wherein the surface tension of the gelatin is sufficiently high to retain at least a portion of the overpressure of the oxygen throughout a predetermined period of time after having been exposed ton atmospheric environment. Glucose and bactericide and/or fungicide agents can be added to facilitate cellular metabolism and decrease the danger of local infections. The solvent can be distilled water or a physiologic saline solution.

Abstract: The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

Abstract: Disclosed are conjugates including a polymer backbone or microbead and binding molecules, such as Fv, Fab, or F(ab').sub.2 fragments of monoclonal antibodies or whole antibodies that are bound through their Fc carbohydrate moieties or have their Fc portion modified so that they cannot effect ADCC or complement-mediated cytolysis, and that are specific for a T cell surface antigen, such as CD3, TCR, CD4, CD8, or CD28 on T cells. The polymer or microbead is preferably made of cross-linked dextran, ficoll, latex, or agarose. The microbeads are preferably of 1 to 10 .mu.m in size, so that they can be suspended in in vivo fluids. These conjugates can be used to induce proliferation of T cells and immune stimulation, and to increase the antibody response against an administered antigen.

Abstract: Described herein is a method for making a flake for use in a topical application. The flake is formed by contacting a liquid phase waxy material that may contain pigments, fragrance, plasticizer, hydrophilic modifier with a pseudoplastic hydrophilic gel, and/or an active ingredient. The waxy material contacts the surface of the gel and after the two materials have contacted, the waxy material is solidified and forms a sheet. This sheet is then broken into pieces to form the flakes of the present invention. The flakes can be used in formulating any topical product that can contain a lipid material.